Clinical Trials Logo

Filter by:
NCT ID: NCT05787522 Recruiting - Breast Cancer Clinical Trials

Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk

Start date: September 30, 2022
Phase:
Study type: Observational

The goal of this clinical trial is to evaluate efficacy and safety of AI-assisted radiotherapy contouring software in CT images for thoracic organs at risk. After screening, qualified participants' thoracic CT images will be anonymized and randomized to two sequences, one with independent investigator contouring of thoracic organs at risk, followed by washout period and software-assisted contouring, and the other in reverse sequence. The washout period lasts for at least 4 weeks. Investigators will not only contour organs at risk in their own center, but also organs in the previous center. The anonymized images will be contoured by independent expert team as the golden standard. The experimental group refers to software-assisted contouring, while the control group refers to independent investigator contouring. Judged by the golden standard, the two groups will be compared to evaluate efficacy and safety of software-assisted contouring of thoracic organs at risk.

NCT ID: NCT05787418 Recruiting - COVID-19 Clinical Trials

HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

Start date: March 31, 2023
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.

NCT ID: NCT05787288 Recruiting - COVID-19 Pneumonia Clinical Trials

A Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19.

Start date: January 23, 2023
Phase: Early Phase 1
Study type: Interventional

This clinical study aims to investigate the safety and efficacy of nebulized inhalation of extracellular vesicles derived from mesenchymal stem cells combined with standard therapy for COVID-19-infected individuals. The primary objective is to determine whether nebulized MSC-secreted extracellular vesicles may be a feasible approach to alleviate COVID-19-induced lung injuries and promote recovery. Participants will be allocated to receive either nebulized MSC-secreted extracellular vesicles twice a day (BID) for 5 days as the test group or nebulized saline solution twice a day for 5 days as the control group. Researchers will compare the test and control groups to evaluate the safety and efficacy of extracellular vesicles in combination with standard therapy.

NCT ID: NCT05787171 Recruiting - Cicatrix Clinical Trials

Three Sutures With Different Absorption Rates for Lower Abdominal Incision

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The previous studies have demonstrated that wedge excision combined modified buried vertical mattress suture (WE-MBVMS) provides better aesthetic outcomes than traditional ways. Prolonged tension reduction is crucial in WE-MBVMS suppressing scar, while suture used during WE-MBVMS decided the length of tension reducing time to a certain degree. However, presently surgeons select suture for WE-MBVMS mostly according to their personal preference and clinical experience and clinical comparative evidence exposing the best suture for desired cosmetic outcome is lacking. Here, investigators purposed to establish a feasibility trial comparing the scars left by WE-MBVMS using sutures with different tension holding time. This is a feasibility, single-center RCT with 35 patients aiming to compare the scar of the hypogastric incision sutured by three different-absorption-rate sutures with WE-MBVMS. The incision induced by donating skin grafts is evenly divided into three segments, each segment randomly uses one of three different sutures randomly allocated by the SAS (V.9.4) statistical software. The feasibility of this study will be assessed by the primary outcomes, including patient and clinician enrolment refusal as well as their reasons, reasons for ineligibility, recruitment ratio, retention and withdrawal at each follow-up point (1, 3, and 6 months), reasons for withdrawal, integrity of collected data and adverse event rates. Secondary outcome measures of the cosmetic outcome of scar will help shape future fully powered RCT by formulating the sample size.

NCT ID: NCT05786989 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Start date: February 28, 2023
Phase: Phase 4
Study type: Interventional

The goal of this interventional study is to evaluate efficiency and safety in prior one-line treated diffuse large B-cell lymphoma. The main questions it aims to answer are: - Complete remission rate - Objective remission rate - Progression-free survival - tolerance Participants will recevied a minimum of 2 and a maximum of 6 cycles of R-GemOx(rituximab 375 mg/m2 IV on day 1 , Gemcitabine 1000 mg/m2, Oxaliplatin 100 mg/m2 IV on day 2) and 60 mg selinexor on days 1, 8, and 15 of each cycle

NCT ID: NCT05786963 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis

Start date: December 29, 2022
Phase:
Study type: Observational

Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled. Patients' clinical characteristics, including alanine aminotransferase, aspartic aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, triglyceride and total cholesterol, hepatitis B surface antigen, steatosis, and liver stiffness measurement will be collected. The consistence of liver fibrosis and steatosis assessment between Hepatus and FibroScan will be evaluated in this study.

NCT ID: NCT05786950 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

To investigate the relationship among the neural respiratory drive (NRD), the sensation of the dyspnea and the effect of the bronchodilator on each stage COPD patients.

NCT ID: NCT05786872 Recruiting - Clinical trials for Alcohol Use Disorder

Efficacy and Safety of Dual-target DBS for Treatment-resistant Alcohol Use Disorder

Start date: July 5, 2023
Phase: N/A
Study type: Interventional

This is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of dual-target deep brain stimulation for treatment-resistant alcohol use disorder.

NCT ID: NCT05786859 Recruiting - Hepatitis B Clinical Trials

The Efficacy and Safety of Rifaximin Treatment

Start date: March 9, 2023
Phase: Early Phase 1
Study type: Interventional

There will be 124 patients diagnosed as hepatitis B associated acute on chronic liver failure with mild to moderate hepatic encephalopathy will be enrolled in this study according to the inclusion and exclusion criteria, and will be randomly divided into two groups as 1:1.First group is called Rifaximin group, on the basis of comprehensive treatment of liver failure, Rifaximin (Alfa Sigma S.p.A) is added, three times a day, 400 mg each time, for a total of 4 weeks, and observed until 12 weeks after withdrawal. The other group is called standard treatment group (control group), which will receive routine comprehensive treatment for liver failure. The reversal of mild to moderate hepatic encephalopathy in the two groups of patients will be observed within 4 weeks, then follow up to 12 weeks.

NCT ID: NCT05786846 Recruiting - Thyroid Dysfunction Clinical Trials

Serum Thyroid Function After Iodinated Contrast Administration

Start date: February 15, 2023
Phase:
Study type: Observational

This study investigated the changes in serum thyroid function and urinary iodine levels before and after the use of iodinated contrast to analyze the prevalence of thyroid dysfunction in the Chinese euthyroid adults after using iodinated contrast.